• LAST PRICE
    74.8300
  • TODAY'S CHANGE (%)
    Trending Down-1.8100 (-2.3617%)
  • Bid / Lots
    74.6900/ 4
  • Ask / Lots
    74.9700/ 4
  • Open / Previous Close
    75.3400 / 76.6400
  • Day Range
    Low 73.7500
    High 76.2000
  • 52 Week Range
    Low 23.0950
    High 89.3900
  • Volume
    269,381
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 76.64
TimeVolumeNUVL
09:32 ET1065074.495
09:34 ET454674.45
09:36 ET237674.02
09:38 ET432573.875
09:39 ET389273.98
09:41 ET161374.415
09:43 ET10074.66
09:45 ET10074.3325
09:48 ET664175.035
09:50 ET50075.24
09:52 ET55075.05
09:54 ET170075.255
09:56 ET877075.26
09:57 ET347075.13
09:59 ET526675.02
10:01 ET10075.06
10:03 ET70075.09
10:06 ET80074.9425
10:08 ET20074.72
10:12 ET20074.49
10:14 ET10074.495
10:15 ET67474.58
10:19 ET376974.53
10:21 ET200074.76
10:24 ET78174.71
10:26 ET20074.815
10:30 ET80074.695
10:32 ET20074.56
10:33 ET20074.4
10:35 ET430275.01
10:37 ET411174.9
10:39 ET2591174.8925
10:44 ET155075.01
10:46 ET114474.87
10:48 ET10074.86
10:50 ET24474.93
10:53 ET10074.95
10:55 ET30074.95
10:57 ET80075
11:00 ET10075.015
11:02 ET360074.725
11:04 ET90074.82
11:06 ET230074.88
11:08 ET10074.885
11:09 ET70074.94
11:11 ET450075.025
11:13 ET478075.32
11:15 ET70475.2
11:20 ET447775.6
11:24 ET40075.925
11:26 ET65075.9
11:27 ET20075.825
11:29 ET10075.85
11:31 ET50075.895
11:33 ET410076.07
11:36 ET83376.08
11:38 ET150076
11:40 ET20076.01
11:42 ET10076.005
11:44 ET33975.79
11:45 ET20075.89
11:47 ET30075.73
11:49 ET30075.82
11:54 ET60075.87
11:56 ET60075.92
11:58 ET10075.87
12:00 ET179875.9
12:05 ET60075.74
12:09 ET30075.535
12:12 ET40075.45
12:14 ET190175.67
12:16 ET60075.645
12:18 ET133775.7
12:23 ET20075.61
12:25 ET70075.69
12:27 ET110075.62
12:30 ET10075.58
12:32 ET50075.32
12:34 ET20075.4
12:36 ET30075.32
12:38 ET249475.345
12:41 ET40075.36
12:43 ET40075.25
12:45 ET20075.15
12:48 ET174775.08
12:50 ET30075.01
12:52 ET30075.14
12:54 ET60075.1
12:56 ET10075.09
12:57 ET20075.04
12:59 ET40074.74
01:01 ET50074.6
01:03 ET170574.62
01:06 ET10074.7
01:08 ET2169175.015
01:14 ET94474.83
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNUVL
Nuvalent Inc
4.9B
-34.6x
---
United StatesIMVT
Immunovant Inc
4.7B
-17.4x
---
United StatesBHVN
Biohaven Ltd
4.7B
-9.9x
---
United StatesRVMD
Revolution Medicines Inc
5.2B
-8.5x
---
United StatesKRYS
Krystal Biotech Inc
5.0B
2,014.0x
---
United StatesMDGL
Madrigal Pharmaceuticals Inc
5.3B
-13.3x
---
As of 2024-03-28

Company Information

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Contact Information

Headquarters
One Broadway, 14th FloorCAMBRIDGE, MA, United States 02142
Phone
857-357-7000
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Anna Protopapas
President, Chief Executive Officer, Director
James Porter
Chief Financial Officer, Treasurer
Alexandra Balcom
Senior Vice President - Drug Development
Henry Pelish
Senior Vice President - Translational Development
John Soglia

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.9B
Revenue (TTM)
$0.00
Shares Outstanding
64.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.16
Book Value
$10.94
P/E Ratio
-34.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.